Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, FiscalAI reports.
Matinas Biopharma Stock Performance
NYSEAMERICAN MTNB traded down $0.01 during mid-day trading on Thursday, reaching $0.23. 331,097 shares of the stock were exchanged, compared to its average volume of 2,166,020. The stock has a market capitalization of $1.49 million, a PE ratio of -0.12 and a beta of 1.76. Matinas Biopharma has a 1-year low of $0.23 and a 1-year high of $3.09. The business’s fifty day simple moving average is $0.51 and its 200 day simple moving average is $0.58.
Institutional Trading of Matinas Biopharma
A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent filing with the Securities and Exchange Commission. 11.77% of the stock is currently owned by institutional investors and hedge funds.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
See Also
- Five stocks we like better than Matinas Biopharma
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
